Literature DB >> 2446877

Clinical effects of intravenous iloprost in patients with intermittent claudication.

U Müller-Bühl1, C Diehm, T Krais, R Zimmermann, H Mörl, H H Eckstein.   

Abstract

In a randomized patient-blind study iloprost or hydroxy-ethyl starch 200/0.5 were given i.v. 5 h daily for 2 weeks to 24 patients suffering from severe intermittent claudication due to peripheral vascular disease. An increase in pain-free walking distance of more than 50% occurred in 6 of 11 patients after the iloprost infusions and in 7 of 12 patients after HES treatment. No significant effects on haemodynamic or clinical chemistry tests were observed.

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 2446877     DOI： 10.1007/bf00544555

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN： 0031-6970            Impact factor:   2.953


  14 in total

1.  Pharmacokinetics and pharmacodynamics of the prostacyclin analogue iloprost in man.

Authors:  W Krause; T Krais
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

2.  [Isovolemic hemodilution in stage-IIb peripheral arterial occlusive diseases. Prospective randomized double-blind comparison of middle-molecule hydroxyethyl starch and electrolyte solution].

Authors:  H Kiesewetter; F Jung; J Blume; M Gerhards
Journal:  Dtsch Med Wochenschr       Date:  1986-08-29       Impact factor: 0.628

3.  Antiplatelet effects of intravenous iloprost in patients with peripheral arterial obliterative disease. A placebo-controlled dose-response study.

Authors:  H Darius; V Hossmann; K Schrör
Journal:  Klin Wochenschr       Date:  1986-06-16

4.  The antiplatelet and cardiovascular actions of a new carbacyclin derivative (ZK 36 374)--equipotent to PGI2 in vitro.

Authors:  K Schrör; H Darius; R Matzky; R Ohlendorf
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1981-06       Impact factor: 3.000

5.  [Significance of prostaglandins in arterial thrombosis pathology: survey of an ongoing experience].

Authors:  A Duvivier; J L David
Journal:  Rev Med Liege       Date:  1984-05-01

6.  [Hemodilution therapy of arterial occlusive diseases using hydroxyethyl starch 200/0,5].

Authors:  U Müller-Bühl; H U Comberg; C Diehm; J Allenberg; H Mörl
Journal:  MMW Munch Med Wochenschr       Date:  1982-03-12

Review 7.  The prostacyclin--thromboxane A2 balance: pathophysiological and therapeutic implications.

Authors:  S Bunting; S Moncada; J R Vane
Journal:  Br Med Bull       Date:  1983-07       Impact factor: 4.291

8.  Increased prostacyclin biosynthesis in patients with severe atherosclerosis and platelet activation.

Authors:  G A FitzGerald; B Smith; A K Pedersen; A R Brash
Journal:  N Engl J Med       Date:  1984-04-26       Impact factor: 91.245

9.  Decreased sensitivity of human platelets to PGI2 during long-term intraarterial prostacyclin infusion in patients with peripheral vascular disease--a rebound phenomenon?

Authors:  H Sinzinger; K Silberbauer; A K Horsch; A Gall
Journal:  Prostaglandins       Date:  1981-01

10.  Hemodynamic effects of iloprost, a prostacyclin analog.

Authors:  S Kaukinen; P Ylitalo; T Pessi; H Vapaatalo
Journal:  Clin Pharmacol Ther       Date:  1984-10       Impact factor: 6.875
View more
  3 in total

Review 1.  Pharmacological approaches to the treatment of intermittent claudication.

Authors:  E G Bevan; P C Waller; L E Ramsay
Journal:  Drugs Aging       Date:  1992 Mar-Apr       Impact factor: 3.923

2.  Intravenous infusion of iloprost in arterial occlusive disease: dose-dependent effects on skin microcirculation.

Authors:  L Caspary; A Creutzig; K Alexander
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

3.  Effects of Beraprost sodium on subjective symptoms in diabetic patients with peripheral arterial disease.

Authors:  Hang Seob Yoon; Woo Jin Choi; Il Hoon Sung; Ho Seong Lee; Hyung Jin Chung; Jin Woo Lee
Journal:  Clin Orthop Surg       Date:  2013-05-15
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.